Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy.
D000284:Administration, Oral; D000803:Angiotensin I / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors; D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000503:physiopathology; D024061:Collagen Type III / Q000037:antagonists & inhibitors / Q000235:genetics; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004656:Enalapril / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004719:Endomyocardial Fibrosis / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D006333:Heart Failure / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D006439:Hemodynamics; D006973:Hypertension / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D007262:Infusions, Intravenous; D008297:Male; D010490:Pericardial Effusion; D020913:Perindopril / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D015996:Survival Rate; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000235:genetics; D053773:Transforming Growth Factor beta1; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000235:genetics; D017725:Ventricular Pressure
D024061:Collagen Type III; D012333:RNA, Messenger; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D004656:Enalapril; D000803:Angiotensin I; D020913:Perindopril